Eight seed-stage tech companies were selected late yesterday to be the first class of startups from San Diego to be admitted to the 10-week business technology accelerator program established by Silicon Valley’s Plug and Play Tech Center.
Every company admitted to... Read more »
Not every speech is improved by visual aids. Abraham Lincoln made do without PowerPoint at Gettysburg (though wags have tried to reimagine that), and Franklin Roosevelt’s voice on the radio in 1933 calmed a nation rattled by the Great Depression... Read more »
Amid the hectic pace of earnings releases, we saw a number of partnership agreements and other developments coming out of San Diego’s life sciences community. Here’s my wrap-up.
—Shares of San Diego-based Receptos (NASDAQ: RCPT), a biotech developing new treatments... Read more »
Capas, a private investment firm established in Detroit last year, has acquired E-Learning Mind, a small San Diego ed-tech company that develops learning programs for corporate customers in such areas as sales training, product knowledge, and health and safety procedures.
Financial... Read more »
A big Taiwanese tech company you probably haven’t heard of is starting to make noise in the U.S. Based out of several hubs around the country, it is positioning itself to gain a foothold in the local market for chips used... Read more »
San Diego-based Lumena Pharmaceuticals says today it has raised $23 million in a Series A round that is intended to carry the company through mid-stage trials of its lead drug candidate for treating a rare group of metabolic disorders that cause... Read more »
The three laws of getting a meeting with a VC: 1) If you don’t know somebody who can provide a referral, don’t even try. 2) Start about four months in advance. 3) Once the meeting is on the books, assume that... Read more »
[Corrected 5/6/13, 10:50 am. See below.] San Diego-based Receptos, a biotech developing new treatments for immune disorders, is among 13 IPOs expected to go public this week, according to Renaissance Capital, a financial firm in Greenwich, CT, that specializes... Read more »
Drug development is a tough business. Small companies that dare to try often end up in public train wrecks when they head to Washington to meet the FDA. It’s a shame, a colossal waste, every time a company gets that far... Read more »